Logo

Henlius to Initiate P-III Study of HLX04-O (biosimilar- bevacizumab) in Australia

Share this
Henlius to Initiate P-III Study of HLX04-O (biosimilar- bevacizumab) in Australia

Henlius to Initiate P-III Study of HLX04-O (biosimilar- bevacizumab) in Australia

Shots:

  • Henlius reported that TGA has approved the filing of clinical trial for HLX04-O to treat wet-AMD
  • The two part P-III global study is expected to be initiated in Australia to further evaluate the efficacy & safety of HLX04-O (vitreous injection) in treatment of wAMD
  • HLX04-O is a recombinant anti-VEGF humanized mAb ophthalmic injection and has the potential to be one of the first bevacizumab approved for ophthalmic diseases

 ­ Ref: Henlius | Image: Henlius

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions